Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - film coated tablets - prolonged release - ropinirole as hydrochloride 8 mg - ropinirole - ropinirole - treatment of parkinson’s disease under the following conditions:• initial treatment as monotherapy, in order to delay the introduction of levodopa• in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)."

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole - film coated tablet - 2 mg - active: ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide red lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - ropinirole as hydrochloride - film coated tablets - ropinirole as hydrochloride 0.25 mg - ropinirole - ropinirole - treatment of idiopathic parkinson's disease : ropinirole may be used alone in the treatment of idiopathic parkinson's disease.addition of ropinirole to levodopa may be used to control " on - off " fluctuations and permit a reduction in the total daily dose of levodopa.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - ropinirole as hydrochloride - film coated tablets - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - treatment of idiopathic parkinson's disease : ropinirole may be used alone in the treatment of idiopathic parkinson's disease.addition of ropinirole to levodopa may be used to control " on - off " fluctuations and permit a reduction in the total daily dose of levodopa.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - film coated tablets - prolonged release - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - treatment of parkinson’s disease under the following conditions:• initial treatment as monotherapy, in order to delay the introduction of levodopa• in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)."

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - film coated tablets - prolonged release - ropinirole as hydrochloride 4 mg - ropinirole - ropinirole - treatment of parkinson’s disease under the following conditions:• initial treatment as monotherapy, in order to delay the introduction of levodopa• in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)."

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 2.28 mg (equivalent: ropinirole, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 0.57 mg (equivalent: ropinirole, qty 0.5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 2.28 mg (equivalent: ropinirole, qty 2 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; laureth-8 - repreve is indicated for the treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 0.57 mg (equivalent: ropinirole, qty 0.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; iron oxide yellow; iron oxide red; laureth-8 - repreve is indicated for the treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.